Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02059213 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT02059213 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 72 participants.
The verdict
NCT02059213, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer. The investigators hypothesize that the addition of Palbociclib to initial ADT (Androgen Deprivation Therapy) in patients with newly metastatic RB-positive prostate cancer may significantly increase the efficacy of ADT.
Interventions
- DRUG Bicalutamide
- DRUG Zoladex
- DRUG Ibrance
- DRUG Lupron Depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02059213
The ClinicalTrials.gov registry entry for NCT02059213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bicalutamide is the first listed.
NCT02059213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02059213 about?
NCT02059213 is a clinical study titled "A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer". This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer. The investigators hypothesize that the addition of Palbociclib to initial ADT (Androgen Deprivati...
What is the current status of trial NCT02059213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-06. Estimated completion is 2019-06-04.
What interventions are being tested in trial NCT02059213?
The interventions under investigation include: Bicalutamide (DRUG), Zoladex (DRUG), Ibrance (DRUG), Lupron Depot (DRUG).
Who is sponsoring clinical trial NCT02059213?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.